TY - JOUR T1 - Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin JF - In Vivo JO - In Vivo SP - 2045 LP - 2050 DO - 10.21873/invivo.11702 VL - 33 IS - 6 AU - CHIKAGE NARUI AU - HIROSHI TANABE AU - JASON S. SHAPIRO AU - YOKO NAGAYOSHI AU - TAKENORI MARUTA AU - MOMOKO INOUE AU - YUKIHIRO HIRATA AU - HIROMI KOMAZAKI AU - HIROKUNI TAKANO AU - SHIGEKI NIIMI AU - SEIJI ISONISHI AU - AIKOU OKAMOTO Y1 - 2019/11/01 UR - http://iv.iiarjournals.org/content/33/6/2045.abstract N2 - Background/Aim: Hypersensitivity reactions (HSRs) to carboplatin, a key drug for ovarian cancer patients, are problematic. The aim of this study was to evaluate the efficacy and safety of readministration of platinum agents (PTs) in recurrent ovarian cancer patients who developed HSRs to carboplatin. Patients and Methods: Thirty-one patients with recurrent ovarian cancer who developed HSRs to carboplatin were divided into those who continued to receive PTs in the following cycle (continuation group, n=24) and those in whom either the drug was switched to non-platinum agents (non-PTs) or chemotherapy was ended (discontinuation group, n=7). Outcomes were evaluated based on patients' medical records. Results: The median survival time following HSRs was 28.1 and 15.4 months in the continuation and discontinuation groups, respectively (p=0.018). In the continuation group, a total of 155 cycles of PTs were re-administrated, and 50 cycles (32%) led to recurrent HSRs. There were no recurrent HSRs with a severity of grade 3 or greater. Conclusion: Continuation of PTs in ovarian cancer patients may contribute to improvement in their overall survival without severe recurrent HSRs. ER -